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Objectives: An increasing emphasis on patient-centred health care and shared decision making requires an
intensive consideration of patient preferences. In the present study, patient preferences regarding treatment of HIV/
AIDS were explored using direct assessment and discrete choice experiment (DCE).
Methods: Based on literature research about preferences of HIV/AIDS patients we conducted a qualitative pre-study.
The results were used to compose a questionnaire on relevant aspects of HIV/AIDS treatment which underwent a
pre-test. In the subsequent quantitative study phase presented here, the following data were collected online or on
paper including socio-demographic data, SF12v2, data on HIV/AIDS, antiretroviral treatment and patient preferences
for therapy characteristics using direct measurement, as well as a discrete choice experiment.
Results: 218 patients completed the quantitative main study, 82% of these on paper. 86% were male and the most
frequent age group was between 45 and 54 years (37.6%). The SF12v2 showed a mean value of 43 points for the
“mental health” component sum score. In the direct measurement the most relevant therapy characteristics were
“Self-application of the drug (at home or on-the-go) possible”, “Drug has very high efficacy (reduction of viral load)”
and “Long term (hidden) damage (e.g. organ damage) is unlikely”. Based on a factor analysis, six treatment
characteristics were selected and used to generate eight virtual therapies. To evaluate the patient assessments a
random effect logit model was employed. All of the characteristics were statistically significant predictors of the
model of patient preference. The most important therapy characteristic was that the disease is not obvious for
others.
Conclusions: The main result is the high impact of quality of life, in particular the emotional quality of life on
patient preferences on the selection of treatments. Thus, the selection of particular treatment options should be
accompanied by a deliberate consideration of treatment features, which need to be considered in order to
maximize patient adherence and compliance.Background
Progression to the acquired immune deficiency syn-
drome (AIDS), a disease with failure of the immune sys-
tem caused by the human immune deficiency virus
(HIV), characterized by certain life-threatening oppor-
tunistic infections and malignancies can be prevented by
combined antiretroviral therapy (cART, [1,2]). HIV infec-
tion occurs by mucosal or parenteral body fluid contact,
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reproduction in any medium, provided the origmilk [3]. AIDS was first reported in 1981 [4]. At the end
of 2011, an estimated 34 million people were living with
HIV worldwide. The number of people dying of AIDS
related causes dropped to 1.7 million in 2011, down
from a peak of 2.2 million in 2005. There were 2.5 mil-
lion new HIV infections in 2011. This was 20% less than
in 2001 [5].
One of the factors influencing this decrease is the
availability of cART, which reduces both the mortality
and morbidity associated with HIV infection [3]. HIV
viral suppression, reduced rates of resistance, an increase
in survival, and improved quality of life have been shown
to be strongly correlated with adherence to antiretroviral
therapy [6,7]. Because HIV treatment is a lifelong en-
deavour and because many patients will initiate therapyis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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signs or symptoms of HIV disease, adherence poses a
special challenge and requires commitment from the pa-
tient and the health care team [8].
Characteristics of cART are (i) combination of three or
more antiretroviral drugs, (ii) high impact of continuos
administration (adherence) to avoid the development of
viral resistance, (iii) high potential of drug-drug interac-
tions between antiretrovirals or concomitant therapy,
(iv) moderate to high potential for adverse events, and
(v) requires durable—life long—intake. Additional psy-
chological consequences for the patients result by social
marginalisation as a HIV-infected individuum and po-
tential stigmatisation by long term effects of cART, e.g.
lipodystrophic change of body shape [8].
The present study assesses the therapy-related expec-
tations and needs of HIV/AIDS-patients. In contrast to
clinical trials concerning mainly efficacy and safety as-
pects, the primary goal of this study was the comprehen-
sive evaluation of preferably all relevant aspects of
treatment quality from the patients’ perspective such as
effectiveness, quality of life and further treatment op-
tions. Secondary, we were interested in finding out how
the study participants would judge the relevance of these
criteria.
Methods
The study population was comprised of HIV/AIDS
patients, who completed paper-based and online-
questionnaires. Patient recruitment was performed by
the German Competence Network for HIV/AIDS
(‘Kompetenznetzwerk HIV/AIDS’) located in Bochum,
who helped to distribute paper-based questionnaires
and the link to the online version among treatment
centres. The Competence Network for HIV/AIDS is a
general national research alliance, and as such includes
the most important German working groups active in
clinical and basic research.
Qualitative pre-study
To ensure content validity, a qualitative pre-study was
performed prior to the main study to identify important
aspects of an ideal HIV/AIDS treatment. Based on a
literature search (e.g. [8]), an interview guideline was
composed for group discussions with HIV/AIDS pa-
tients. These patients were interviewed in four focus
groups of five to nine patients.
The results of these interviews were used to design a
questionnaire on relevant aspects describing the quality
of HIV/AIDS treatments from the patient’s perspective.
This questionnaire underwent a pre-test including 28
subjects to ensure its usability. Most of the test items
appeared to be clear and comprehensible. Based on the
results of the pre-test the questionnaire was finalised.Main survey
The main survey was performed from July 2009 until
end of May 2010 using either online or paper question-
naires. Patients were contacted either in writing and
were given the paper-based questionnaire version with
stamped addressed envelopes, or via email/internet. Both
methods were offered since older patients may not have
wanted to use the online version. No personal data such
as addresses, names or phone numbers were collected.
The questionnaire encompassed five main domains:
 Patient characteristics: age, gender, educational level.
 Current health status (Health related Quality of Life
(QoL), SF12v2, German version of the SOEP [socio-
economic panel], [9]).
 Data on HIV/AIDS and antiretroviral therapy: year
of diagnosis, route of infection, year of first
antiretroviral treatment.
 Direct assessment of importance of 26 items on
HIV/AIDS therapy characteristics (five-point Likert
scale ranging from “very important” (100 points) to
“not important” (0 points))
 Assessment of current therapy using 6 therapy
characteristics.
 Discrete Choice Experiment (DCE) for eliciting
patient preferences using eight pairs with six
characteristics each.
Discrete choice experiment
Revealed and stated measurements are the two ap-
proaches for the measurement of patient preferences.
The revealed method is based on observed decisions
being evaluated, e.g. prescription data [10,11]. It shows
how patients decide, but cannot explain why [12]. In
stated analyses patient preferences are collected using
direct questioning: patients have to assess objects with
respect to several characteristics, which are presented in
different combinations. Stated methods, such as conjoint
and discrete choice analysis (DCE), aim to measure the
influence of therapy characteristics on patient prefer-
ences [12]. The conjoint analysis is a statistical method
to determine how people weigh and assess different
characteristics of a product or service. The preference
measurement assumes that each product or service is
characterised by one or more characteristics, which in
sum represent this product or service [11].
The discrete choice experiment is a choice based
method, and a variant of the conjoint analysis, which
was made possible through the theoretical work of
Lancaster [13] and McFadden [14]. In the discrete
choice experiment different therapies are presented pair-
wise and the subjects have to decide for one of the op-
tions [15]. In a first step all characteristics being relevant
for each target group have to be identified. These may
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waiting time for an appointment [16].
The relevant characteristics are then combined to
define hypothetical products or treatment options. As
the number of possible combinations increases exponen-
tially, not all combinations can be presented. It is
important to cover all the relevant fields when selecting
the items for the DCE. Therefore, in most cases a re-
duced sample of alternatives is used, which, however,
allows a reliable evaluation of preferences [17,18]. To ap-
preciate the importance of possible statistical correlation
between main effects and interactions, the number of
combinations was reduced to a more manageable size
without losing essential information through an orthog-
onal design (if certain assumptions about interaction
effects are made). The maximum dissimilarity between
therapy alternatives was achieved by generating the
alternative B as exact mirror image of A (using the fold-
over technique) [19].
The treatment alternatives are presented to the patient
and the patient has to decide for one of the presented
options. Based on the decision behaviour the relevance
of the different characteristics for the decision can be
calculated and described by coefficients.Analysis
We employed a DCE technique with eight pairwise
choice situations, each with six characteristics. Re-
spondents had to choose eight times between treat-
ment A or B. The calculation of coefficients was
performed using the maximum likelihood method.
According to the underlying distribution function, dif-
ferent estimation methods (in most cases probit or
logit estimations) were used [17,20-23]. We tested
models with all the sociodemographic variables in
order to explore differences between subgroups. We
generated interaction-terms of each attribute with each
parameter as product-terms (i.e. each attribute was
interacted with age, sex and so forth). We then calcu-
lated a model with all the main effects and all the inter-
actions of one parameter (“forced entry”). That means
a single model for the whole set of variables. No strata
or separate models for subgroups were applied because
in that case we would have to deal with different
constants. The combined “parsimonious model” was
employed by testing a model with the main effects and
all significant interactions of all parameters resulting
in the analysis above and then reducing the model by
eliminating the non significant interactions step by
step. The resulting model contained all the main
effects and the significant interactions. The aim of
this model was to show all the subgroup effects “at a
glance”.Results
Patient characteristics
Between July 2009 and end of May 2010, 218 patients
completed the questionnaire. Most of the patients (82%)
answered via paper version and 18% online. 86% of the
study participants were male, only 14% were female. The
most frequent age group referred to patients between 45
and 54 years (37.6%). 22% of the patients had a lower
certificate of secondary education, 33% had a general
certificate of secondary school, 43% had a certificate
qualifying for university admission and 2% of the
patients left school without certificate.
Disease and treatment characteristics
The patients were asked to specify the year in which
their HIV/AIDS disease was diagnosed. The answers
covered a range from 1982 to 2010. The mean of pri-
mary diagnosis was the year 1998 with a standard
deviation of 7.3 years.
The most frequent route of infection was MSM (men
having sex with men) with 55% of the patients. 12% of
the patients reported heterosexual contacts, 5% iv drug
use and 4% blood transfusions. For 24% of the patients
the route of infection was unknown.
The question if their AIDS disease has already “broken
out” was answered with “no” in 64% of the patients. The
patients were asked to specify the year in which the first
antiretroviral treatment was initiated for them. Answers
were available in 205 of the 218 patients (94%). Eight
patients specified that they have not yet received any
antiretroviral treatment (5 patients with missing data).
The answers on start of AIDS treatment cover a range
from 1984 to 2010. The mean of the first antiretroviral
treatment was the year 2001 with a standard deviation
of 6.5 years.
A summary of patient data is shown in Table 1.
Direct assessment of AIDS therapy characteristics
The respondents had to rate the importance of 26 ther-
apy characteristics. The mean assessments of importance
are included in Table 2. All except 3 of the items
concerning quality of treatment were of relatively high
mean importance (>70 points) for the patients. These
ceiling effects are not surprising, since only aspects were
presented that were rated as being important according
to the literature and the qualitative pre-study.
Factor analysis
Using factor analysis higher-level dimensions were found
to summarise the importance assessments. Using a
Principal Components Analysis (PCA) including varimax
rotation, six factors were found declaring 60.2% of the
variance of the 26 items. The rotated factor matrix is
shown in Table 2.








Paper and pencil 82%
Online 14%
Most frequent route of infection 55% MSM
Antiretrovirally treated 94%
Health status (SF12v2)
Mental health (mean) 43 points
Physical health (mean) 50 points
Mean year of primary diagnosis (SD) 1998 (7.3)
Mean year of first AIDS treatment (SD) 2001 (6.5)
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lowing semantic descriptions: factor 1 covers the social
situation, everyday life and social quality of life, factor 2
flexibility of medication, factor 4 efficacy and life expect-
ancy, factor 5 physical and emotional quality of life and
factor 6 long term side effects. Factor 3 covers several
aspects combining dosing, treatment interruptions, extra
payment and pregnancy.
The most relevant therapy characteristics represented
by mean assessments of more than 90 points were:
– Self-application of the drug is possible,
– Drug has very high efficacy,
– Long term (hidden) side effects are unlikely.
Assessment of current therapy
The first step for the patients was to assess their current
therapy using these six therapy characteristics. In most
cases the patients assessed their current therapy as posi-
tive demonstrated by assessments “yes”, “rather yes” or
“probably yes” in 64% to 96% of the patients. In detail,
more than 90% of the patients assessed their therapy to
provide maximal increase of life expectancy and allow
participation in social life and 84% of the patients
assessed that their therapy avoids that the disease is
obvious for others.
Socio-demographic baseline characteristics
Using analyses of variance, the importance assessments
were evaluated for effects of socio-demographic baseline
characteristics of the patients: older patients prefer drugs
which can be dosed according to current health status.
For female patients it is important that pregnancy ispossible. If HIV/AIDS has already broken out, treatment
aspects such as therapy free intervals, flexible dosing,
less tablets and discrete intake are more important than
for average patients.
Preferences in the discrete choice experiment
Discrete choice experiments are limited to the use of
only a few characteristics. Based on the pre-study and
on the results of the factor, six characteristics were se-
lected and described by a positive and a negative pole
helping to distinguish clearly between treatments (see
Table 3). As these six characteristics are corresponding
to the 6-factor-solution of the factor analysis, they were
assumed to cover the relevant range of treatment char-
acteristics. The final definition of the items “long term
side effects” (<20% vs. ≥20% of patients) and “flexibility
of dosing” (max. 3 vs. ≥4 tablets/day) was due to clinical
expertise.
Generation of pairs
Based on the six therapy characteristics eight virtual
therapies were generated. These eight therapies were
presented to the patients in eight pairs from which the
patient had to select one of the two therapies (A or B).
In total, 1604 valid observations were available. Some
of the respondents did not evaluate any or all pairs. On
average, out of 214 respondents who finished at least one
pair comparison, 7.5 pairs were available (range 1–8).
In both of the chosen treatments physical, emotional
and social quality of life were positive, combined either
with maximum increased life expectancy (pair 8) or less
long term damage (pair 4). A random effect logit model
was created, which takes the partial dependency of ob-
servations from the same person concerning the param-
eter estimation into account. Estimated coefficients and
their standard errors are shown in Table 4.
All of the treatment characteristics were statistically
significant predictors of the model of patient prefer-
ences. The characteristic “Emotional quality of life” was
the most important, followed by “Physical quality of life”
and “Social quality of life”. Less important but still
statistically significant were the items “Life expectancy”,
“Flexibility of dosing” and “Long term side effects
improbable”.
A supplementary partial log likelihood analysis as pro-
posed by Lancsar et al. [24] yielded a similar hierarchy
as the interpretation based on the item coefficients.
In additional evaluations, socio-demographic parame-
ters were analysed. Subgroup effects were found particu-
larly for “Emotional quality of life”, which was significantly
less important for older patients, patients with longer dur-
ation of infection and patients being under therapy for a
longer period. MSM patients, however, found this charac-
teristic more important, as well as the characteristic
Table 2 Mean importance of therapy characteristics and factor weightings for the 6-factor model (items sorted by
weighting)
Item No. Therapy characteristic (short form) Mean importance 1 2 3 4 5 6
10 Self-application of the drug is possible 94 .569 .312 .328
1 Drug has very high efficacy 94 .716
18 Long term (hidden) side effects unlikely 92 .620
2 Maximum prolongation of life expectancy 90 .688
4 Drug does not generate resistance 90 .383 .599
20 Drug does not affect appearance 89 .317 .410
19 Drug improves physical state 89 .400 .513
3 Drug allows further therapy options 88 .716
16 Rarely occurring nausea 86 .868
17 Rarely occurring diarrhoea 86 .842
14 Drug can be taken along without problems 85 .659
7 Long duration of efficacy 85 .384 .315 .381
6 Long term use of the drug is possible 84 .323 .419
23 Drug allows improved mobility 82 .789
12 Flexible application 82 .729
21 Emotional and mental state improved 81 .749
5 Can be used also in case of comorbidities 80 .488 .386
13 Simple application: only few tablets 79 .736
22 Social contact opportunities improved 78 .820
24 Drug does not cause additional costs 75 .492 .539
11 Once daily application 73 .703 .362
15 Inconspiciuous drug intake 73 .318 .404 −.462
25 Treatment does not require much time 71 .600 .345
9 Dosing of drug may vary 60 .742
8 Therapy-free intervals possible 51 .713
26 Pregnancy allowed 30 .524
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education maximum increase of life expectancy was more
important.
Each pair comparison was accompanied by an assess-
ment of whether the patient would change his or her
current therapy in favour of the treatment of choice of
the corresponding pair. “No change” answers ranging
between 73% and 89% demonstrate a high degree of
satisfaction with the current therapy.Table 3 Treatment characteristics for discrete choice experim
Characteristics Positive pole (+
Life expectancy maximal increas
Long term side effects improbable (<20% of p
Flexibility of dosing max. 3 tablets/da
Physical quality of life diarrhoea or nausea less
Emotional quality of life disease not obvious fo
Social quality of life participation in social lifeAt the end of the questionnaire, the patients were asked
to give an assessment of the degree of difficulty they had
in performing the paired comparisons in the DCE. 8%
found it “very difficult”, 29% said it was “rather difficult”,
36% gave a medium ranking (“some comparisons more
difficult than others”), 18% thought it was “not very diffi-
cult” and 8% claimed they had “no problems at all” in com-
pleting the DCE. This means that overall, the DCE can be
considered as feasible from the patients’ point of view.ent
) Negative pole (−)
e moderate increase
atients) possible (≥20% of patients)
y ≥4 tablets/day
frequent diarrhoea or nausea more frequent
r others disease obvious for others
possible participation in social life restricted
Table 4 Results of random effects logit model (discrete choice experiment; negative pole as reference group)
Characteristics Coefficient SE (coeff.) Sig. Partial log likelihood
Life expectancy: maximal increase 0.735 0.152 *** −717.7
Long term side effects improbable (<20%) 0.408 0.147 ** −709.5
Flexibility of dosing: max. 3 tablets/day 0.454 0.151 ** −710.1
Physical quality of life: diarrhoea, nausea less frequent 1.611 0.152 *** −769.4
Emotional quality of life: disease not obvious for others 2.984 0.153 *** −981.7
Social quality of life: participation in social life possible 1.140 0.153 *** −735.4
Model constant −3.726 0.214 ***
***: p < 0.001, **: p < 0.01.
Model parameters:
Wald Chi2 (df = 6) = 470.81.
Log likelihood = −705.7.
Prob > Chi2 = 0.0000 (i.e. p < 0.001, ***).
Prob ≥ Chi2 = 1.000.
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The patient view and desires in healthcare decisions (e.g.
treatment characteristics) are often not sufficiently
considered. However, in times of limited healthcare
resources, both shared decision making and patient
involvement in treatment decisions have been encour-
aged in recent years. This requires an understanding of
patient priorities concerning treatment decision making.
The present study collects and depicts the preferences
of HIV/AIDS patients in Germany regarding their
therapy. Based on a qualitative study to ensure content
validity, a quantitative preference measurement was
performed including a direct assessment and a choice-
based measurement of patient preferences (DCE). This
latter technique allows the estimation of the relative
importance of different aspects of care and the trade-
offs between these aspects, while the direct assessment
allows the inclusion of more aspects. Hence, both
methods should be used in a combined way.
The current patient sample includes a proportion of
43% patients with certificate qualifying for university ad-
mission. Compared to the KompNet data set of more
than 9,000 patients with HIV/AIDS [25] presenting a
rate of 33% of the male patients with higher education
entrance qualification [26], the current patient sample
seems to have an increased rate of patients with higher
level of education. However, as the educational level
seems to have only limited effect on the preference
structure, a possible bias may be of minor effect. In total,
there is no reason to assume that the documented
patient preferences will be biased substantially by sample
effects.
The current health status was assessed by the SF12v2
questionnaire (version 2 for the socio-economic panel,
SOEP). The mean value of 43 points for the “mental
health” component summary score is 0.7 standard devia-
tions below the German average. This indicates that the
adults with HIV/AIDS of this sample assess their mentalhealth as worse compared to the assessments of the
German population norm. In contrast, the mean value
for the “physical health” component summary score of
50 points indicates an assessment of the HIV/AIDS
patients being not different from the population norm.
The results of the SF12v2 subscales confirm this
picture: in particular the subscales “role emotional” and
“social functioning” which both belong to the “mental
health” component summary score fall quite clearly
below the average of the population norm.
In the main study patients had to assess a total of 26
treatment characteristics which had been shown to be
relevant by literature research and the qualitative pre-
study. As expected, the results demonstrate a ceiling
effect of the assessments, which were found predomin-
antly in the upper range of the scales, perhaps because
mainly important characteristics were presented as a re-
sult of the qualitative pre-study. The top of the priority
list is marked by needs such as high efficacy, the avoid-
ance of long term and short term side effects, but also
by the improvement of emotional and social status.
In a second step the preferences were evaluated using
a discrete choice experiment. During this experiment
the patients had to choose 8 times between two fictitious
treatments, each characterized by 6 characteristics. The
used analysis model allowed determining the amount to
which each characteristic contributed to the treatment
choice.
The highest relevance for the treatment choice of the
patients was found for emotional quality of life being
mainly characterized by the characteristic that the dis-
ease was not obvious for other persons. The next rele-
vant patient-relevant outcome from the patient point of
view were the avoidance of physical impairments such as
diarrhoea and vomiting and the facilitation to participate
in social life. Being still statistically significant, the
characteristic “maximum increase of life expectancy”
followed at some distance. The reduction of the risk of
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flexibility of dosing (intake of 3 tablets per day vs. 4 or
more tablets) seemed to be less important for the treat-
ment choice.
The results of the DCE correspond partly to the direct
assessment where emotional, physical and social quality
of life were also in the upper range of needs. Surpris-
ingly, however, the characteristics “maximum increase of
life expectancy” and “avoidance of the risk of long term
damage” seem to be far less important in DCE than in
the direct assessment of importance. DCE results em-
phasise to see HIV/AIDS more as a chronic disease than
as directly life threatening. This corresponds well to im-
pairments of mental health found in the SF-12 question-
naire. As a consequence, using quality of life arguments
rather than efficacy and safety aspects may increase
therapy adherence of the patients. However, these argu-
ments differ from the known aspects like pill count,
dosing frequency and adverse events shown by Stone
et al. [27] or resistance, regimen convenience and sleep
disturbance shown by Beusterien et al. [28]
The subgroup analyses have shown that the most im-
portant characteristic “emotional quality of life” was
weighted even higher in some subgroups such as youn-
ger patients, MSM patients (together with physical qual-
ity of life) and patients with shorter duration of infection
and treatment. Presumably, in these patients the under-
standing of HIV/AIDS as a long term disease is intensi-
fied, highlighting aspects of a life being impaired by the
disease as little as possible. Furthermore, patients with a
higher level of education (“Abitur”, i.e. high-school
diploma) assessed the characteristic “maximum increase
of life expectancy” as relatively more important.
Based on these considerations, some limitations of the
current study may be discussed. Because the DCE is only
manageable using a few characteristics and pairs to be
compared, decisions need to be made during construc-
tion of comparisons. In principle, the composition of
characteristics reflects the factor structure found in the
direct measurement. In doing this, however, some
problems remained: for example, dosing aspects were
presented as maximum 3 tablets per day versus more,
whereas the direct assessment revealed more facets of
application such as dosing according to current health
status, treatment-free periods or self-application. As
these and some more aspects of application affected at
least two factors in the factor analysis, the characteristic
“dosing flexibility” may have been defined too simply to
reflect the complexity of dosing characteristics. Further-
more, the definition of poles of the characteristics may
have influenced the preference decisions: the item
“increase of life expectancy” was presented as “increase”
versus “maximum increase”. Maybe the perceived differ-
ence between these two poles was too small to preferthis characteristic against others. Thus, the somewhat
surprising low importance of this efficacy parameter
may be the consequence of too close definitions of the
poles of this characteristic.
Although our recruitment procedure did not guaran-
tee representativeness, the sample fits quite well to the
expected picture of HIV/AIDS patients. For instance, the
rate of female patients (14%) corresponds well to the
rate of the KompNet cohort (15%) [26], and the propor-
tion of patients with MSM (men having sex with men)
as source of infection of 55% in the current sample cor-
responds well to the rates of 56% for the ClinSurv HIV
cohort and 55% of national German HIV surveillance
data reported by Bätzing-Feigenbaum et al. [29]. The
proportion of 94% of patients reporting being treated
with antiretroviral therapy at some time during their
HIV/AIDS disease in the current sample appears to be
higher than in the total sample of HIV/AIDS patients,
being specified between 75% and 80% by the RKI
Bulletin [30]. However, for our research question the
quality of answers may even benefit from a higher rate
of treated patients.
Conclusion
In summary, direct assessments as well as DCE contrib-
ute important findings to the knowledge of preference
structures of patients suffering from HIV/AIDS. The
main result of the current study may be the fact that it
is very important for HIV/AIDS patients that their anti-
retroviral therapy supports their quality of life, in par-
ticular the emotional quality of life. This might reflect a
paradigm shift in the grading of preferences since more
convenient and less toxic options for cART became
available within the last decade. Thus, the selection of a
particular treatment regimen should be accompanied by
a deliberate consideration of features of possible treat-
ment options, which need to be considered in order to
maximise patient adherence and compliance to the se-
lected treatment.
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